Charlotte L. Mortensen
Stockholm, AB, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Preclinical efficacy and dosimetry of CD44v6-directed terbium-161 radionuclide therapy.
Journal: Theranostics
Published: March 28, 2026
Author Correction: Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer.
Journal: Scientific reports
Published: July 29, 2025
Affinity maturation and optimization of CD44v6-targeting antibodies for molecular radiotherapy.
Journal: Nuclear medicine and biology
Published: February 28, 2025
Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer.
Journal: Scientific reports
Published: July 14, 2023
The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer Model.
Journal: Frontiers in oncology
Published: February 05, 2020
Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib.
Journal: Frontiers in oncology
Published: February 03, 2020
The HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: an in vitro and in vivo approach.
Journal: Scientific reports
Published: October 04, 2019
The Stapled Peptide PM2 Stabilizes p53 Levels and Radiosensitizes Wild-Type p53 Cancer Cells.
Journal: Frontiers in oncology
Published: June 12, 2019
Showing 1-9 of 9
Last Updated: 09/26/2026